Risedronate is a pyridinyl bisphosphonate. It is licensed for prevention and treatment of both postmenopausal and corticosteroid-induced osteoporosis at a recommended dose of 5mg daily.
The overall incidence of adverse effects in trials with risedronate is similar to placebo, even for upper GI events. Patients with active GI disease or on NSAIDs were not excluded from these trials.
Last reviewed 01/2018